Quidel Co. (NASDAQ:QDEL) Director Kenneth F. Buechler sold 9,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $66.50, for a total transaction of $598,500.00. Following the completion of the transaction, the director now owns 56,769 shares in the company, valued at approximately $3,775,138.50. The sale was disclosed in a legal filing with the SEC, which is available through this link.

NASDAQ QDEL traded up $0.50 during trading on Thursday, hitting $67.34. The company’s stock had a trading volume of 177,338 shares, compared to its average volume of 256,209. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.79 and a current ratio of 1.21. The company has a market cap of $2.63 billion, a PE ratio of 23.88, a P/E/G ratio of 0.96 and a beta of 1.37. Quidel Co. has a fifty-two week low of $44.27 and a fifty-two week high of $77.63.

Quidel (NASDAQ:QDEL) last released its earnings results on Wednesday, February 13th. The company reported $0.75 EPS for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.21. Quidel had a return on equity of 31.73% and a net margin of 14.20%. The firm had revenue of $132.59 million during the quarter, compared to the consensus estimate of $132.26 million. During the same quarter in the previous year, the company posted $0.56 earnings per share. The company’s revenue was up 15.4% compared to the same quarter last year. On average, sell-side analysts predict that Quidel Co. will post 2.77 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Cutler Group LP acquired a new stake in shares of Quidel during the fourth quarter worth about $43,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Quidel by 16.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,353 shares of the company’s stock valued at $115,000 after acquiring an additional 333 shares during the period. Quantamental Technologies LLC acquired a new position in Quidel in the fourth quarter valued at approximately $149,000. Meeder Asset Management Inc. lifted its holdings in Quidel by 383.5% in the third quarter. Meeder Asset Management Inc. now owns 2,659 shares of the company’s stock valued at $173,000 after acquiring an additional 2,109 shares during the period. Finally, Alambic Investment Management L.P. acquired a new position in Quidel in the third quarter valued at approximately $205,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently issued reports on the stock. ValuEngine cut shares of Quidel from a “buy” rating to a “hold” rating in a research note on Friday, March 1st. Barclays reiterated a “buy” rating and issued a $74.00 target price on shares of Quidel in a research note on Friday, February 15th. Zacks Investment Research lowered Quidel from a “buy” rating to a “hold” rating in a research note on Saturday, February 16th. Craig Hallum lifted their target price on Quidel from $51.00 to $63.00 and gave the company a “hold” rating in a research note on Thursday, February 14th. Finally, BidaskClub upgraded Quidel from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 4th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company’s stock. Quidel presently has a consensus rating of “Buy” and a consensus target price of $71.50.

COPYRIGHT VIOLATION NOTICE: “Quidel Co. (QDEL) Director Kenneth F. Buechler Sells 9,000 Shares” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/quidel-co-qdel-director-kenneth-f-buechler-sells-9000-shares/2890622.html.

About Quidel

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

Read More: Systematic Risk and Investors

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.